Background
==========

Abdominal aortic aneurysm (AAA) is an irreversible, progressive dilation of the abdominal aorta, occurring most frequently below the renal arteries. Known risk factors for AAA include smoking, male sex, comorbid vascular disease, increasing age, and family history \[[@B1]\]. AAA pathophysiology is complex, but fundamentally aneurysms arise from the loss of structural integrity and the consequent weakening of the vessel wall. Several extracellular matrix (ECM) degrading enzymes, including matrix metallopeptidases (MMPs) \[[@B2]\], cathepsins \[[@B3],[@B4]\], and granzyme \[[@B5]\], have been implicated in the destruction and turnover of ECM proteins in the aortic wall. Infiltrating cells of the immune system are also found throughout the AAA wall \[[@B6]\] and are important to AAA development by producing ECM degrading enzymes and reactive oxygen species, as well as releasing proinflammatory cytokines that lead to further inflammation \[[@B7],[@B8]\].

AAA also displays several characteristics consistent with being a multifactorial genetic disease \[[@B9]\]. Approximately 15% of AAA patients have a positive family history \[[@B10]\] and genetic association studies have identified risk alleles in cardiovascular risk genes such as *DAB2IP*\[[@B11]\], *CDKN2BAS*\[[@B12]\], *AGTR1*\[[@B13],[@B14]\], *ACE*\[[@B13],[@B14]\], and *MTHFR*\[[@B14]\]. These polymorphisms, however, explain only a small fraction of an individual\'s genetic risk for AAA. A genome-wide DNA linkage analysis using an affected relative pair approach with covariates by our laboratory identified two linked chromosomal regions on 19q13 and 4q31 \[[@B15]\]. Linkage to chromosome 19q was replicated in a separate study in Dutch families using different statistical analyses \[[@B16]\]. Chromosome 19q13 may harbour risk alleles for several aneurysm phenotypes, as linkage to this region has also been reported for intracranial aneurysms \[[@B17]-[@B19]\] and the Kawasaki disease \[[@B20]\].

Several functional candidate genes reside within the chromosome 19 candidate interval. Peptidase D (*PEPD*; prolidase) is a manganese-dependent dipeptidyl peptidase that cleaves iminopeptides with C-terminal proline or hydroxyproline, which is the terminal step in collagen degradation \[[@B21]\]. The chromosome 19q candidate interval also contains several genes that may be relevant to immune system function in AAA. *CD22*is a sialic-acid binding protein expressed in B-lymphocytes, which can inhibit signalling through the B-cell receptor and therefore alter B-cell function \[[@B22]\]. B-cells are found in the AAA wall and *CD22*has been implicated in autoimmune pathologies characterized by similar inflammatory and ECM changes seen in some AAAs \[[@B23]\].

Here we report on an analysis of candidate genes selected from the chromosome 19q13 linkage interval. Nine functional positional candidate genes (*PEPD*, *CEBPA*, *CEBPG*, *GPI*, *HAMP*, *CD22*, *NFKBID*, *TYROBP*, and *HCST*) were identified as having annotated function in either the immune system or in ECM turnover. Fifty-five SNPs covering the major haplotype blocks in each gene were selected. Two genes with evidence of association, *CD22*and *PEPD*, were investigated further by exon sequencing and immunohistochemical staining of aneurysmal and non-aneurysmal aortic tissue samples.

Methods
=======

Human samples for genotyping
----------------------------

AAA cases used in genotyping (n = 394; 79% male) were collected at the University of Pittsburgh, the University of Liége in Liége, Belgium, and Dalhousie University Hospital in Nova Scotia, Canada. Canadian controls were spouses of AAA cases. Belgian controls were patients with diagnoses other than AAA and treated at the same hospital as the AAA cases. Details on the recruitment have been published previously and the samples have been used in prior genetic association studies \[[@B12],[@B24],[@B25]\]. The collection of samples was approved by the Institutional Review Board of Wayne State University and each recruitment site.

DNA isolation and whole genome amplification (WGA)
--------------------------------------------------

Genomic DNA used in genotyping and sequencing was isolated from peripheral blood as described previously \[[@B25]\]. A total of 10 ng of genomic DNA was amplified by strand-displacement amplification \[[@B26]\] with Phi29 polymerase using the Genomiphi Kit (GE Healthcare Biosciences, Piscataway, NJ) according to the manufacturer\'s instructions. Amplified DNA was diluted 1:100 for use in genotyping and DNA sequencing reactions.

RNA isolation and cDNA synthesis
--------------------------------

Total RNA was isolated from cultured skin fibroblasts as previously described \[[@B27]\]. cDNA was prepared from 250 ng of RNA using SuperScript III First-Strand Synthesis Supermix (Invitrogen, Carlsbad, CA). Residual RNA was removed by RNAse H treatment.

Genetic association study
-------------------------

Genes in the linkage interval on chromosome 19 were prioritized functionally using Gene Ontology (GO) \[[@B28]\] and Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@B29]\] annotations. mRNA expression of each gene in AAA and control abdominal aorta was also assessed using data from a previously described microarray-based mRNA expression profiling study \[[@B30]\]. Altogether 55 SNPs with a minor allele frequency (MAF) of 0.10 or greater that were representative of major haplotype blocks in the Caucasian population were identified in and around the nine positional functional candidate genes selected for the study. Each SNP was assessed for its SNP quality score from Illumina and a custom Illumina BeadChip was designed using those SNPs considered to have sufficient designability. The SNPs are listed in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1.

Power calculations were performed using the Genetic Power Calculator \[[@B31]\] (<http://pngu.mgh.harvard.edu/~purcell/gpc/>). We assumed that the polymorphism and the disease locus were in complete linkage disequilibrium (LD) and that they had the same allele frequencies, i.e., the polymorphism was the disease locus. Assuming a disease locus with an additive effect and a disease prevalence of 0.02, our sample size of 394 cases and 419 controls had an 80% power to detect a susceptibility locus with a genotypic relative risk (GRR) ≥ 1.2 (2.4 for two copies of risk alleles) at a significance level of 0.05 for a SNP with a high risk allele frequency (HAF) ≥ 0.2.

SNPs were genotyped using the Illumina GoldenGate assay \[[@B32]\] and the call rate of each SNP was evaluated using GenCall Software (version 6.1.3.28, Illumina, San Diego, CA). Deviation from Hardy-Weinberg equilibrium (HWE) was evaluated using an exact test \[[@B33]\] as implemented in Haploview \[[@B34]\] and nominal p-values without correction for multiple testing are reported in Additional File [1](#S1){ref-type="supplementary-material"}. Allelic association was tested using a Pearson χ^2^test with one degree of freedom (DF). To assess the potential for population stratification, HWE and allelic association were also tested separately in the Belgian and Canadian subpopulations. An additional test of association was performed using the general linear mixed model approach implemented in the Statistical Analysis for Genetic Epidemiology (S.A.G.E.) \[[@B35]\] program ASSOC, which yields both Wald and likelihood ratio test (LRT) statistics. Both tests gave very similar results and therefore, we report only results from the LRT which is considered more robust in small sample sizes. False discovery rates (FDR) are reported for the LRT. Haplotype association was analyzed using a score test \[[@B36]\] implemented in the haplo.score function in the package HaploStats for the R statistical language and environment \[[@B35]\]. For genes with evidence of association, LD plots were generated from the case and control genotypes separately using HaploView to examine LD structure.

DNA sequencing of functional positional candidate genes
-------------------------------------------------------

Genomic DNA and RNA samples used in DNA sequencing are listed in Additional files [2](#S2){ref-type="supplementary-material"} (Table S2) and [3](#S3){ref-type="supplementary-material"} (Table S3). Primer pairs to amplify the coding sequence of *CEBPG*, cDNA sequence of *PEPD*, and exonic sequences of *CD22*were designed using PrimerQuest^SM^, a primer design tool based on Primer3 software \[[@B37]\] available on the Integrated DNA Technologies website (<http://www.idtdna.com/Scitools/Applications/Primerquest/>; IDT, Coralville, IA). Primers were selected using predicted melting points, primer hairpins and primer-dimer interactions calculated using the SciTools programs in PrimerQuest^SM^. DNA amplification by PCR was performed under the following conditions. Final concentrations were 50 mM KCl, 1.5 or 2 mM MgCl~2~(primer-pair specific; see Additional file [4](#S4){ref-type="supplementary-material"}, Table S4), 2 μM dNTPs, 0.167 μM of each primer, 0.025 U/μl AmpliTaq Gold enzyme (Applied Biosystems) in 10 mM Tris-HCl, pH 8.3. Template DNA constituted 1/10^th^of the final volume for WGA-genomic DNA or 1/20^th^for cDNA. Template was denatured by heating to 94°C for 10 minutes, which was followed by 40 cycles of denaturation (94°C), annealing (variable) and elongation (72°C), and a final three-minute elongation incubation at 72°C. Detailed cycle times and annealing temperatures are found in Additional file [4](#S4){ref-type="supplementary-material"}, Table S4.

PCR products were separated by agarose gel electrophoresis to assess the sizes of bands and the specificity of the reaction. PCR products with single clean bands of the correct molecular weight were purified for DNA sequencing using Montage™ PCR purification columns (Millipore, Billerica, MA).

DNA sequencing was performed using the Cycle Sequencing (Applied Biosystems, Foster City, CA) method at the Applied Genomics Technology Center (AGTC) at Wayne State University. Primers used for DNA sequencing can be found in Additional file [5](#S5){ref-type="supplementary-material"}, Table S5. Sequence variants were identified by alignment of sequences using BioX software (available at <https://www.lagercrantz.name/projects/biox>) and manual examination of the sequence plots.

Functional analysis of sequence variants
----------------------------------------

To assess the potential function of identified sequence variants, *in silico*functional analyses were carried out. The SIFT (Sorting Intolerant from Tolerant) algorithm \[[@B38]\] was used to predict the structural effects of non-synonymous substitutions. NetPhos \[[@B39]\] was used to predict the creation or destruction of phosphorylation sites. To assess the potential effect of 3\'-untranslated region (UTR) sequence variants on microRNA (miRNA) binding, predicted binding sites were obtained from the MicroCosm Targets Database \[[@B40],[@B41]\] (<http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>).

Immunohistochemical staining to analyze protein expression in human aortic tissues
----------------------------------------------------------------------------------

Control non-aneurysmal aortas (n = 7) were obtained post-mortem at autopsy. Exclusion criteria were known malignancy or systemic infection. AAA tissues (n = 9) were obtained from elective surgical repair operations when the aneurysmal sac was trimmed as part of surgery. Tissue samples were removed solely for the purpose of graft placement and would otherwise be discarded. Tonsil (for CD22) or kidney (for PEPD) tissue were used as positive controls. Nonspecific IgG in lieu of primary antibody served as a negative control. All tissue samples were fixed in buffered formalin solution, routinely processed and then embedded in paraffin. Details on aortic samples used can be found in Additional file [6](#S6){ref-type="supplementary-material"}: Table S6.

Immunohistochemical staining was carried out using 5 μm sections of formalin-fixed paraffin embedded aortic tissue. Sections were dried in an oven and deparaffinized using sequential rinses in Histoclear xylene substitute (National Diagnostics U.S.A., Atlanta, GA), 100% ethanol, 95% ethanol and water. Heat-induced antigen retrieval was performed by microwave-treatment of slides submerged in citrate buffer. Endogenous peroxidase was blocked by placing slides in 3% methanol/peroxide block solution for 10 min. The slides were incubated with primary antibody directed against PEPD (1:250 dilution; catalog number 12218-1-AP, Proteintech Group, Inc., Chicago, IL) or CD22 (1:100 dilution; catalog number ab953, Abcam Inc., Cambridge, MA) on an automatic immunostainer (Autostainer, DAKO, Carpinteria, CA). A secondary antibody with avidin-biotin peroxidase amplification from DAKO was used and the signal detected using diaminobenzidine as a chromogen.

Results
=======

Selection of functional candidate genes on AAA1 locus
-----------------------------------------------------

The AAA1 linkage interval (Figure [1](#F1){ref-type="fig"}) spans approximately 4 Mbp from 33 Mbp to 37 Mbp (NCBI build 37.3) on chromosome 19q13 and contains over 100 genes. In order to identify a smaller set of strong candidate genes for further study, GO and KEGG functional annotations were used to identify nine genes with functions relevant to AAA pathogenesis (Table [1](#T1){ref-type="table"}). Eight of these genes were selected based on an annotated function in the immune system, as immune involvement in AAA pathogenesis has been well studied \[[@B7]\]. Additionally, *PEPD*, was identified as a candidate gene based on its activity in collagen turnover and potential for contributing to ECM remodelling in the AAA wall \[[@B21]\].

![**Map of relative positions of candidate genes in the AAA1 linkage interval**. The relative positions of the nine candidate genes studied are shown above (plus strand) or below (minus strand) the black scale bars depending on the direction of transcription. The positions of genotyped SNPs are indicated at the top as gray lines.](1471-2350-12-14-1){#F1}

###### 

Functional positional candidate genes studied by genetic association

  Symbol     GO Category                    KEGG Pathway                                SNP (N)   AAA Exp   Cont Exp   **Diff Score**^**1**^
  ---------- ------------------------------ ------------------------------------------- --------- --------- ---------- -----------------------
  *PEPD*     NA                             NA                                          25        1300      957        10.52
  *CEBPG*    immune response; others        NA                                          2         222       252        -3.27
  *CEBPA*    myeloid cell differentiation   NA                                          16        630       118        31.32^2^
  *GPI*      humoral immune response        NA                                          5         1136      759        11.57
  *HAMP*     immune response; others        NA                                          1         136       ND         13.57
  *CD22*     immune response; others        B-cell receptor signaling pathway           4         578       ND         16.17
  *NFKBID*   inflammatory response          NA                                          1         22.4      ND         23.80^2^
  *TYROBP*   cellular defense response      natural killer cell mediated cytotoxicity   1         4973      801        41.15^2^
  *HCST*     NA                             natural killer cell mediated cytotoxicity   0         736       148        33.44^2^

Nine genes were identified within the AAA linkage intervals on chromosome 19 (AAA1 locus) with annotated GO or KEGG functions relevant to AAA. mRNA expression levels for each gene in both AAA and control abdominal aortic tissue, as well as a score indicating the differences in expression levels (Diff score), were obtained from our previously published work, details of which can be found in \[[@B30]\] and the microarray data can be obtained at the Gene Expression Omnibus (GEO) database (Series\# GSE7084; <http://www.ncbi.nlm.nih.gov/geo/>).

^1^The Diff Score is generated using a custom algorithm from Illumina. A Diff Score of 13 corresponds to an approximate p value of 0.05.

^2^Significantly different between AAA and control tissues after correction for multiple testing (FDR \<0.05).

Chr, chromosome; NA, not applicable; ND, not detected; Exp, Expression; Cont, Control

Since genes not expressed in aortic tissue, either diseased or non-diseased, would be less likely to contribute to aneurysm formation, mRNA expression of each candidate gene was assessed using microarray expression profiles of AAA and control aortic tissue. As all of the genes selected by functional annotation were expressed in either AAA or control abdominal aorta, no genes were excluded by this criterion. Furthermore, four of these genes, *CEBPA*, *NFKBID*, *HCST*and *TYROBP*, had significantly higher expression in AAA tissue than in age-, sex-, and ethnicity-matched control aortas and *CD22*was expressed only in AAA tissue (Table [1](#T1){ref-type="table"}).

Candidate gene association study
--------------------------------

Fifty-five SNPs in or around the nine functional candidate genes found in the AAA1 locus were genotyped. Eleven SNPs were excluded from further analysis since they were either monomorphic or had low genotype call rates (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). This number can be considered high, but is expected in a custom array where several of the SNP assays had not been previously validated. Additionally, the excluded SNPs were located in *CEPBA*and *PEPD*, where the genotyping coverage was excellent even without including the failed assays. Testing for deviation from HWE was performed in the remaining 44 SNPs and four SNPs (rs7248389, rs752237, rs736289 and rs4239576) that showed deviation were identified (Additional file [1](#S1){ref-type="supplementary-material"}, Table S1). One of the four SNPs also showed evidence of association and since deviation from HWE can result from association, this SNP (rs7248389) was included in the final analysis. Three of the four SNPs did not show evidence of association, and were subsequently excluded (rs752237, rs736289 and rs4239576) from further analysis leaving 41 SNPs for the final analyses. In the cases of these three variants the deviation from HWE was likely due to technical problems in genotyping.

Using an allelic χ^2^test of association, eight SNPs in three genes, *CD22*(2 SNPs), *PEPD*(5 SNPs), and *HAMP*(1 SNP), were identified as being nominally associated with AAA (p \< 0.05; Table [2](#T2){ref-type="table"}). When tested for genotypic association using logistic regression, six of these SNPs were nominally associated, two were not associated, and an additional SNP in *GPI*was identified (Table [2](#T2){ref-type="table"}). Although not significantly associated, SNPs in *NFKBID*did approach nominal significance (p \< 0.10) by this test. In Table [2](#T2){ref-type="table"} we also present the FDR-values for the LRT statistics. Only the association with rs7248389 in *PEPD*remained significant when correcting for multiple testing.

###### 

Genetic association study results for SNPs with nominal p \< 0.05.

  ----------------------------------------------------------------------------------------------------------------------------
  SNP           Gene     Alleles\        MAF (Cases; Controls)\         LRT                                        
                         (Minor/Major)   **χ**^**2**^**test P-value**                                              
  ------------- -------- --------------- ------------------------------ -------------- -------------- ------------ -----------
  rs7248389     *PEPD*   T/C             0.395; 0.478                   0.404; 0.493   0.379; 0.469                

                                         **0.0009**                     **0.0220**     **0.0084**     **0.001**    **0.037**

  rs889140^1^   *PEPD*   C/T             0.326; 0.395                   0.328; 0.411   0.320; 0.386                

                                         **0.0043**                     **0.0248**     0.0513         **0.0025**   0.088

  rs2267574     *CD22*   A/T             0.105; 0.147                   0.106; 0.180   0.110; 0.129                

                                         **0.0112**                     **0.0047**     0.4185         **0.016**    0.15

  rs2241380     *PEPD*   G/A             0.419; 0.362                   0.436; 0.371   0.404; 0.356                

                                         **0.0184**                     0.0831         0.1536         **0.035**    0.185

  rs756796      *CD22*   A/G             0.280; 0.230                   0.273; 0.222   0.289; 0.234                

                                         **0.02**                       0.1179         0.068          **0.016**    0.164

  rs7250833     *PEPD*   T/C             0.332; 0.282                   0.328; 0.278   0.337; 0.285                

                                         **0.0317**                     0.1582         0.0987         **0.043**    0.219

  rs7251432     *HAMP*   A/G             0.511; 0.459                   0.520; 0.437   0.506; 0.472                

                                         **0.0361**                     **0.0296**     0.5193         0.050        0.210

  rs11880064    *PEPD*   C/T             0.415; 0.364                   0.431; 0.371   0.402; 0.360                

                                         **0.0367**                     0.1045         0.2124         0.059        0.190

  rs580391      *GPI*    A/C             0.203; 0.243                   0.196; 0.245   0.218; 0.243                

                                         0.0519                         0.1143         0.4012         **0.038**    0.237
  ----------------------------------------------------------------------------------------------------------------------------

Tests for allelic association were carried out by a χ^2^test for each SNP. P-values \< 0.05 are shown in bold. The genotypic test of association was performed using the general linear mixed model approach implemented in the Statistical Analysis for Genetic Epidemiology (S.A.G.E.) \[[@B35]\] program ASSOC, which yields the likelihood ratio test (LRT) and the Wald statistics. Only LRT results are reported here since both LRT and Wald gave similar results. SNPs are ranked here by χ^2^test p-value in the combined population. In the alleles column minor allele is listed first based on the results seen in controls. For rs7251432 the minor allele was different for cases than controls.

^1^SNP was out of Hardy-Weinberg equilibrium in Belgian controls.

Since there were multiple associated SNPs in *PEPD*and *CD22*, the LD structure of the genotyped SNPs in each gene was examined using LD plots (Additional file [7](#S7){ref-type="supplementary-material"}, Figure S1 and Additional file [8](#S8){ref-type="supplementary-material"}, Figure S2).

To identify population-specific effects, allelic association was evaluated in the Canadian and Belgian subpopulations separately (Table [2](#T2){ref-type="table"}). For a majority of the SNPs identified above, evidence of association was stronger in the Canadian subpopulation. Four SNPs (rs2267574, rs7248389, rs889140, and rs7251432) were nominally associated in the Canadian subpopulation, but only one of these (rs7248389) showed evidence for association in the Belgian subpopulation. One associated SNP located in *PEPD*(rs7248389) showed nominal deviation from HWE. All nominally associated SNPs and their p-values for the different tests are summarized in Table [2](#T2){ref-type="table"}.

Haplotypic tests of association were also performed on SNPs in *CD22*and *PEPD*. Using a sliding window of five consecutive SNPs, nominally significant haplotypic association (p = 0.0026) was identified in the region of *PEPD*at the SNPs rs10500265-rs6510383-rs7248389-rs7250833-rs2241380 (Table [3](#T3){ref-type="table"}). Nominally significant haplotypic association (p = 0.0065) was also identified in two SNPs in CD22 (rs756796-rs2267574) (Table [3](#T3){ref-type="table"}).

###### 

Significantly associated haplotypes in *PEPD*and *CD22*genes

  Gene and SNPs in the haplotype   Alleles   Haplotype   Haplotype                                    
  -------------------------------- --------- ----------- ----------- ------- ------------------------ --------
  *PEPD*                                                                                              
                                             \[CTTCA\]   0.328       0.367   Reference                
  rs10500265                       C/G       \[CTCCA\]   0.136       0.154   1.049 \[0.761, 1.445\]   
  rs6510383                        C/T       \[CTTCG\]   0.066       0.068   1.062 \[0.687, 1.644\]   
  rs7248389                        C/T       \[CCCCA\]   0.115       0.096   1.422 \[0.997, 2.028\]   0.0026
  rs7250833                        C/T       \[CTCCG\]   0.021       0.013   1.872 \[0.745, 4.706\]   
  rs2241380                        A/G       \[GCCTG\]   0.095       0.075   1.512 \[1.020, 2.242\]   
                                             \[CTCTG\]   0.226       0.188   1.435 \[1.087, 1.894\]   
  *CD22*                                                                                              
  rs756796                         A/G       \[GA\]      0.105       0.147   0.716 \[0.528,0.971\]    
  rs2267574                        A/T       \[GT\]      0.615       0.623   Reference                0.0065
                                             \[AT\]      0.280       0.230   1.253 \[0.995, 1.577\]   

The most common haplotype was used as a reference (OR of 1) and the other haplotypes were compared to that.

DNA sequencing of exons in candidate genes with putative association
--------------------------------------------------------------------

Three genes, *CD22*, *CEBPG*, and *PEPD*, were chosen for DNA sequencing. No significantly associated SNPs were detected within *CEBPG*, but it was chosen for sequencing since it is in close proximity to *PEPD*and could plausibly contribute to the association signal detected in that gene. *CD22*was also considered an intriguing candidate gene since it was expressed in AAA tissue and its expression was not detectable in non-aneurysmal abdominal aorta.

Since the functional consequences associated with exon sequence changes are often easier to predict than with intronic sequences, exon sequencing covering a minimum of the protein coding regions of each gene was performed. The protein coding region of *CEPBG*was sequenced from the genomic DNA of 21 AAA cases, 10 familial and 11 sporadic, and two controls. *CEBPG*has a large 3\'-UTR that we chose not to sequence because of the relatively weak evidence for association within the gene. No sequence variants were identified within the regions sequenced and therefore no further analysis was pursued with this gene.

*PEPD*contains 15 small exons that are spaced over a large genomic distance. cDNA was used as a template for sequencing since the spliced transcript could be covered in only three PCR reactions. Seven sequence variants were identified in *PEPD*when 21 AAA cases and two controls were analyzed (Table [4](#T4){ref-type="table"}; Figure [2A](#F2){ref-type="fig"}; Additional file [9](#S9){ref-type="supplementary-material"}, Table S7; Additional file [10](#S10){ref-type="supplementary-material"}, Table S8). Six individuals showed no variation in their *PEPD*sequence, 12 were heterozygous for one variant, four were heterozygous for two variants and one individual was homozygous for the minor allele of one variant (Additional file [9](#S9){ref-type="supplementary-material"}, Table S7). Four of the seven variants were present in only 1/23 (1/46 alleles) individuals, one was present in 3/23 (3/46 alleles), one in 5/23 (5/46 alleles) and one in 9/23 (10/46 alleles) (Additional file [9](#S9){ref-type="supplementary-material"}, Table S7).

###### 

Sequence changes detected by cDNA sequencing of *PEPD*

      **Chr. Pos. (Build 37)**^**1**^   Gene Feature   Allele Change   SNP Identifier   **MAF (Caucasian)**^**2**^   mRNA Position   Amino Acid   **Residue Change**^**3**^
  --- --------------------------------- -------------- --------------- ---------------- ---------------------------- --------------- ------------ ---------------------------
  1   33,953,912                        Exon 9         T- \> C         rs3745969        0.063                        793             220          Y- \> Y
  2   33,902,652                        Exon 11        T- \> C         rs74988985       0.021                        877             248          G- \> G
  3   33,882,255                        Exon 13        C- \> T                          0.021                        1231            366          H- \> H
  4   33,882,222                        Exon 13        C- \> T         rs17569          0.104 (0.155)                1264            377          H- \> H
  5   33,878,845                        Exon 14        G- \> A                          0.021                        1427            432          A- \> T
  6   33,878,837                        Exon 14        C- \> T         rs17570          0.229 (0.246)                1436            435          L- \> F
  7   33,878,340                        Exon 15        G- \> T                          0.021                        1525            464          L- \> L

^1^Chromosomal position obtained from the National Center for Biotechnology Information (NCBI).

^2^MAF calculated for each SNP from sequencing data on 23 individuals presented in the current study. MAFs in parentheses are from HapMap CEU or other Caucasian population available at the NCBI website.

^3^Single letter amino acids codes are used in Residue Change column.

Chr. Pos., Chromosomal position; MAF, minor allele frequency.

For details, see Additional file [9](#S9){ref-type="supplementary-material"}, Table S7 and Additional file [10](#S10){ref-type="supplementary-material"}, Table S8.

![**Sequence variants identified by candidate gene sequencing**. Variants in *PEPD*(A) and *CD22*(B) plotted to show their relative chromosomal positions and positions relative to gene features. Exons are indicated by the boxes above the x-axis. *PEPD*is transcribed right to left (minus strand) and *CD22*is transcribed left to right (plus strand). Chromosomal coordinates are in kilobase pairs (kb).](1471-2350-12-14-2){#F2}

Three of the *PEPD*sequence variants identified were novel, in that they were not in either the dbSNP or Celera databases. Two SNPs coded for non-synonymous amino acid changes: rs17570, which results in a leucine to phenylalanine substitution at amino acid position 435, and a novel variant resulting in an alanine to threonine substitution at amino acid 432 (Table [4](#T4){ref-type="table"}).

*CD22*has 14 exons and was sequenced from genomic DNA because closer exon spacing allowed for multiple exons to be covered in a single reaction. A total of 20 sequence variants were identified, including five novel variants when analyzing 22 AAA cases and 3 controls (Table [5](#T5){ref-type="table"}; Figure [2B](#F2){ref-type="fig"}; Additional file [11](#S11){ref-type="supplementary-material"}, Table S9; Additional file [12](#S12){ref-type="supplementary-material"}, Table S10). Five variants were in the protein-coding region, including three coding for non-synonymous amino acid substitutions, and six were found within the 3\'-UTR. All but one of the 25 individuals were heterozygous for at least one sequence variant. Two individuals showed a high degree of variability and were heterozygous for seven variants (Additional file [11](#S11){ref-type="supplementary-material"}: Table S9).

###### 

Sequence changes detected by *CD22*exon sequencing

       Chr. Pos. (Build 37)   Gene Feature   Allele Change   SNP Identifier   MAF (Caucasian)   mRNA Position   Amino Acid   Residue Change
  ---- ---------------------- -------------- --------------- ---------------- ----------------- --------------- ------------ ----------------
  1    35,823,999             Intron 3       C- \> T         rs881456         0.021 (0.000)                                  
  2    35,824,019             Intron 3       C- \> G         rs10419538       0.104 (0.181)                                  
  3    35,829,381             Intron 6       A- \> G         rs7248108        0.042 (0.042)                                  
  4    35,831,986             Exon 7         C- \> T         rs25677          0.042 (0.000)     1529            484          C- \> C
  5    35,832,381             Exon 8         G- \> A                          0.021             1721            548          R- \> K
  6    35,832,886             Intron 9       T- \> A                          0.021                                          
  7    35,835,940             Intron 10      C- \> T         rs45453699       0.313                                          
  8    35,836,512             Exon 12        A- \> G                          0.021             2293            739          R- \> G
  9    35,836,530             Exon 12        G- \> A         rs10406069       0.104 (0.292)     2311            745          G- \> D
  10   35,836,600             Exon 12        C- \> A         rs34826052       0.042             2381            768          P- \> P
  11   35,837,148             Intron 13      G- \> A         hCV25603572      0.021 (0.05)                                   
  12   35,837,150             Intron 13      C- \> T                          0.021                                          
  13   35,837,327             Intron 13      C- \> T         rs58156121       0.063                                          
  14   35,837,428             Intron 13      G- \> A         rs12985354       0.208 (0.383)                                  
  15   35,837,694             3\'-UTR        C- \> T         rs73031792       0.250             2715                         
  16   35,837,705             3\'-UTR        A- \> G         rs35529786       0.167             2726                         
  17   35,837,724-5           3\'-UTR        GC I/D^1^       rs34472317       0.042             2745-6                       
  18   35,837,813             3\'-UTR        C- \> T                          0.042             2834                         
  19   35,837,846             3\'-UTR        C- \> T         rs16970255       0.042 (0.000)     2867                         
  20   35,838,076             3\'-UTR        C- \> T         rs3088063        0.042 (0.055)     3097                         

^1^Variant allele is GC insertion.

For definitions, see footnote to Table 4.

For details, see Additional file [11](#S11){ref-type="supplementary-material"}, Table S9 and Additional file [12](#S12){ref-type="supplementary-material"}, Table S10.

Three of the sequence variants identified in the *CD22*were non-synonymous (R \> K, R \> G and G \> D) amino acid changes (Table [5](#T5){ref-type="table"}). Two of the three were very rare (MAF = 0.02), whereas one (rs10406069) had a MAF = 0.104. We tested this variant for genetic association in our case-control set, but found no differences in the allele or genotype frequencies between cases and controls.

Predicted functional changes
----------------------------

Several *in silico*analyses were used to predict whether any of the observed sequence changes might alter protein function or regulation of gene expression. To assess the potential effect of non-synonymous amino acid substitutions, each sequence variant was analyzed with the SIFT algorithm, which predicts whether amino acid changes will not be tolerated. SIFT predicted that all five amino acid substitutions coded by the sequence variants identified in *CD22*and *PEPD*would be tolerated. Structural modeling of *PEPD*demonstrated that the identified amino acid substitutions A432T and L435F, resided in close proximity in a region that appeared to tolerate structural changes (not shown).

The 3\'-UTR of many genes acts as a binding site for miRNAs in post-transcriptional gene regulation \[[@B42]\]. To find out if any of the six sequence variants identified in the 3\'-UTR of *CD22*might interrupt miRNA binding, predicted miRNA binding sites were obtained from MicroCosm database. We found no evidence that the variants changed the binding sites of any miRNAs (not shown).

CD22 and PEPD proteins are expressed in aortic wall
---------------------------------------------------

Protein expression of *CD22*and *PEPD*in the aorta was confirmed by immunohistochemical staining of paraffin-embedded tissue sections of AAA and control abdominal aorta (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Staining demonstrated expression of PEPD protein in both AAA and control sections; expression was observed in fibroblasts and myofibroblasts in the media-adventitia border in both aneurysmal and non-aneurysmal tissue samples. Consistent with previous observations \[[@B43]-[@B45]\], staining for CD22 protein showed an expansion of lymphocytes in AAA tissue as compared with non-aneurysmal aorta.

![**Immunohistochemical staining of CD22 demonstrates expression in AAA tissue associated lymphocytes**. Immunohistochemical staining using a commercially available specific antibody against CD22 was performed on formalin-fixed paraffin embedded tissue sections of non-aneurysmal abdominal aorta (A) and AAA (B, C, D). Negative control staining with non-immune serum showed no staining (data not shown). Images are centered on lymphocytes (small round cells with sparse cytoplasm) primarily seen in the adventitial layer. The adjacent media is indicated with an asterisk. Positive staining appears reddish-brown with hematoxylin counterstaining in blue.](1471-2350-12-14-3){#F3}

![**Immunohistochemical staining of PEPD demonstrates expression in both aneurysmal and non-aneurysmal aortic tissue**. Immunohistochemical staining using a commercially available specific antibody against PEPD was performed on formalin-fixed paraffin embedded tissue sections of non-aneurysmal abdominal aorta (A, B) and AAA (C, D) with staining observed in medial (A) and adventitial layers of controls and throughout the aneurysmal wall. Negative control staining with non-immune serum showed no staining (data not shown). Regions of positive staining appear reddish-brown with hematoxylin counterstaining in blue.](1471-2350-12-14-4){#F4}

Discussion
==========

Strong evidence of linkage exists on chromosome 19 in the AAA1 locus \[[@B15],[@B16]\], but no specific risk loci have yet been discovered. We identified nine functional positional candidate genes within this interval for further study by genetic association. Two of these, *PEPD*and *CD22*, showed evidence of nominal association in multiple SNPs, although only one SNP remained significant after correction for multiple testing. Additionally, significant five- and two-SNP haplotypes were identified for *PEPD*and *CD22*, respectively.

Evidence of association in *PEPD*and *CD22*, was of considerable interest. Based on gene function, gene expression, and protein expression, these genes are plausible candidates for contributing to the risk of developing an AAA. The role of PEPD in collagen metabolism makes it a strong functional candidate for AAA. Although it is unlikely that complete loss of PEPD function alters AAA risk, given that it results in the severe phenotype of prolidase deficiency, polymorphisms that alter PEPD activity could contribute to AAA formation, particularly if they resulted in increased enzymatic activity \[[@B46]\]. Increased PEPD activity has been associated with increased collagen production, both in *in vitro*experiments \[[@B21],[@B47]\] and in keloid scars \[[@B48]\]. Excess collagen production is observed in AAA tissue \[[@B49]\], and has been suggested to contribute to weakening of the aneurysm wall \[[@B50]\]. PEPD is also regulated by several mechanisms relevant to AAA pathogenesis. Nitric oxide, which may contribute to AAA formation \[[@B51]\], upregulates PEPD activity \[[@B47]\]. Similar to other metalloproteases, PEPD activity is sensitive to doxycycline \[[@B52]\], a tetracycline antibiotic with anti-inflammatory properties that have been studied for their therapeutic potential in AAA \[[@B53]-[@B56]\]. Estrogen can regulate PEPD *in vitro*\[[@B57],[@B58]\], an interesting observation given that AAA is six times more common in men than women \[[@B1]\]. Finally, increased serum activity of PEPD has been associated with diseases such as asthma \[[@B59]\], coronary artery disease \[[@B60]\], and fatty liver disease \[[@B61]\].

CD22 is a sialic-acid binding protein found on cells of B-cell lineage. It can inhibit signaling through the B-cell receptor \[[@B22]\], suggesting that impairment of gene function might lead to dysregulation of the immune response and either autoimmune disease or increased inflammation. Supporting this hypothesis is evidence of a role for CD22 in systemic sclerosis; anti-CD22 autoantibodies contribute to systemic sclerosis pathogenesis \[[@B62]\] and there is evidence of association between a SNP in *CD22*and limited cutaneous systemic sclerosis \[[@B23]\]. Systemic sclerosis is characterized by immune infiltration and excessive fibrosis, both of which are observed in AAA subtype known as inflammatory AAA \[[@B63]\]. Given that patients with inflammatory AAA are more likely to have a positive family history \[[@B64]\], *CD22*polymorphisms could contribute to AAA risk. On the other hand, *Cd22*knockout mice display a minimal phenotype with no evidence of increased autoimmune disease \[[@B22]\]. It is plausible, however, that polymorphisms in *CD22*could modulate the immune response in an inflammatory disease such as AAA through changes in the amount of CD22 protein produced in a cell or an alteration of the gene\'s function in B-cell signalling.

Exon sequencing of *PEPD*and *CD22*showed that both have polymorphic coding regions. Polymorphisms that did not result in amino acid substitution or changes to the 3\'-UTR were not considered further, since their functional effects are difficult to predict. After investigation for predicted functional consequences, all of the sequence changes identified in the coding regions or 3\'-UTR of *CD22*and *PEPD*appeared to be tolerated.

One limitation of this study was that the sample size used for genetic association provided only modest power. Although we did observe nominal association in several genes, only one remained significant after correction for multiple testing. Our results should, however, be considered in light of the prior evidence of linkage on chromosome 19q13. While this evidence does indicate the presence of variants contributing to AAA risk at this locus, the differences between linkage and association do not make identification of associated variants a given. Linkage is tolerant of allelic heterogeneity, whereas a variant must be sufficiently common to be detected by association. Therefore, a biologically relevant variant in a linked region may exhibit either weak association, as we observed, or no evidence of association (extensive allelic heterogeneity). Furthermore, if there is also locus heterogeneity in genetic risk factors between populations, increasing sample size using subjects from a different population than that originally studied may actually decrease the evidence of association observed. In light of this and our observation of association at multiple SNPs for each gene, we consider our findings for *PEPD*and *CD22*worth additional studies.

It is possible that the associations seen here resulted from spurious associations or from population stratification. A recent association study examining SNPs from the chromosome 19 linkage interval in the Dutch population found several nominally associated SNPs but none remained significant for multiple testing \[[@B65]\]. Interestingly, the SNP showing the strongest evidence of association resided in *CEPBG*, which is in agreement with our observation of association in the region of *CEBPG*and *PEPD*(Figure [1](#F1){ref-type="fig"}).

Finally, by focusing on functional candidate genes rather than genotyping the entire linkage region, it is possible that linked and associated genes were overlooked. The strategy presented here was based on reducing the number of tests due to the limited power of our sample and the increased ability to interpret associations in genes of known function. Recent technological improvements in high-throughput sequencing provide a potentially more efficient approach to follow-up of linkage results \[[@B66],[@B67]\]. Deep sequencing at high coverage of linkage intervals in members of linked families has identified novel loci. For late age-at-onset diseases the lack of complete nuclear pedigrees and inability to identify definitively unaffected individuals, will reduce the approach to affected relative pair sequencing.

Conclusions
===========

In the present study nine functional positional candidate genes on AAA1 locus on chromosome 19 were investigated. Two of the genes, *CD22*and *PEPD*showed modest level of evidence of being involved in AAA pathogenesis. This evidence came from a nominal association of SNPs residing in these genes to AAA, identification of novel sequence changes and expression of these proteins in aneurysmal tissue. If replicated in independent studies, the findings provide important information about AAA pathogenesis.
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**Figure S1. Linkage disequilibrium (LD) plots of genotyped SNPs in *CEBPG*and *PEPD*for cases (A) and controls (B) separately**. LD at the *CEBPG*/*PEPD*locus plotted separately for cases and controls using r^2^as the statistic. Approximate locations of genes and SNPs were plotted along the x-axis above plots. Nominally associated SNPs are indicated with an asterisk.
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**Figure S2. LD plots of genotyped SNPs in *CD22*for cases (A) and controls (B) separately**. LD at the *CD22*locus plotted separately for cases and controls using r^2^as the statistic. Approximate location of *CD22*and SNPs were plotted along the x-axis above plots. Nominally associated SNPs are indicated with an asterisk.
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**Table S9. *CD22*sequence changes by sample number**. Table showing genotype at each sequence variant detected by sequencing in each individual sequenced. Sample numbers refer to Additional file [2](#S2){ref-type="supplementary-material"}, Table S2, and sequence change number refers to Table [5](#T5){ref-type="table"}.
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